Search papers, labs, and topics across Lattice.
This narrative review addresses the complex management of periprosthetic joint infection (PJI) following tumor megaprosthetic reconstruction, a complication with reported rates of 5-25%. The review summarizes current evidence on risk factors, diagnostic approaches, and treatment outcomes specific to this patient population, highlighting knowledge gaps to inform future research and clinical practice. It emphasizes the higher PJI rates compared to conventional hip and knee arthroplasty.
This review highlights the unique challenges in managing PJI after tumor megaprosthetic reconstruction, emphasizing the need for tailored diagnostic and treatment strategies due to the elevated risk compared to standard arthroplasty.
Simple Summary Periprosthetic joint infection (PJI) is a devastating complication, leading to high morbidity and complex management. Reported PJI rates after primary tumor megaprosthetic reconstruction ranged from 5% to 25%, significantly higher than the 0.5% to 2% observed in conventional hip and knee arthroplasty. The management of PJIs after tumor megaprosthetic reconstruction is complex. This narrative review aims to provide a comprehensive and critical summary of the current understanding of PJIs following tumor megaprosthetic reconstruction. It will specifically focus on analyzing the evidence behind risk factors, diagnostic approaches, and treatment outcomes, and will identify persistent knowledge gaps to guide future research and clinical practice.
